Want to join the conversation?
$NRG 2Q15 Call: NRG has continued the positive momentum starting in the first quarter of the year by reporting second quarter adjusted EBITDA of $729MM, which gives us $1.569Bil of adjusted EBITDA through the first half of 2015, and keeps us on track to achieve a full-year result comfortably within our $3.2-3.4Bil guidance range.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.